Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Acculis' new device for destroying unwanted tissues receives European CE Mark clearance

Acculis Limited today announced the regulatory clearance of its revolutionary new device for destroying unwanted tissues, such as liver tumours. The clearance under the European CE Mark system allows the company to begin deliveries for treating patients throughout Europe and elsewhere where the CE Mark system is recognised. The device is a single high power high frequency 2.45GHz microwave needle that burns a 5cm sphere of tissue in just 5 minutes which is between 3 to 10 times faster than old school radiofrequency based systems or lower frequency 915MHz microwave systems.

27 Feb 2010

Cell Therapeutics files 2009 Annual Report on Form 10-K

Cell Therapeutics, Inc. today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2009. This filing is available for review on CTI's website at www.CellTherapeutics.com, or on the Securities and Exchange Commission's website at www.sec.gov.

27 Feb 2010

Micrometastases in axillary lymph nodes associated with poorer overall survival in breast cancer patients

Metastases that were 2 millimeters or less in diameter ("micrometastases") in axillary lymph nodes detected on examination of a single section of the lymph nodes were associated with poorer disease-free and overall survival in breast cancer patients, according to a new study published online February 26 in the Journal of the National Cancer Institute.

27 Feb 2010

Vion Pharmaceuticals' Onrigin SPA: FDA responds

VION PHARMACEUTICALS, INC. announced today that it had received a response from the U.S. Food and Drug Administration on a Special Protocol Assessment for its oncology therapeutic Onrigin™ (laromustine) Injection.

26 Feb 2010

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.

26 Feb 2010

Magellan Health Services reports net revenue of $2.64 billion for year ended December 31, 2009

Magellan Health Services, Inc. today reported net revenue of $2.64 billion, net income of $106.7 million, or $3.01 per diluted common share, and segment profit of $227.2 million for the year ended December 31, 2009.

26 Feb 2010

Larynx preservation using chemotherapy followed by radiation is effective treatment: Study

Head and neck cancer patients receiving induction chemotherapy followed by radiation to preserve their larynx have a low-risk of severe voice disability and almost half experienced no eating or swallowing problems, according to a first of its kind study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Integrative oncology program aims to address cancer patients' needs from every angle

The very instant Penny Kukovec was diagnosed with breast cancer her world permanently changed. Suddenly, it felt as if her life was out of her control. She felt powerless and overwhelmed. There were so many unanswered questions.

26 Feb 2010

Rapid, multiplexed genotyping method to identify SNPs that affect warfarin dose developed

Researchers from the Ohio State University have developed a rapid, multiplexed genotyping method to identify the single nucleotide polymorphisms (SNPs) that affect warfarin dose. The related report by Yang et al, "Rapid Genotyping of SNPs Influencing Warfarin Drug Response by SELDI-TOF Mass Spectrometry," appears in the March 2010 issue of the Journal of Molecular Diagnostics.

26 Feb 2010

imaGenes GmbH passes certification process to qualify as Roche NimbleGen CSP for DNA Methylation Analysis

Roche NimbleGen is pleased to announce that imaGenes GmbH, located in Berlin, Germany, has passed the certification process to qualify as a Roche NimbleGen Certified Service Provider for DNA Methylation Analysis. imaGenes is a solution provider for functional genomics and proteomics with a comprehensive portfolio of high-quality services for molecular life sciences.

26 Feb 2010

Massaging advanced cancer patients for 14 minutes can reduce stress: Study

Advanced cancer patients who regularly received massages averaging 14 minutes or more by a partner or family member declined in stress scores over four weeks, according to results of a study reported at the 7th annual conference of the American Psychosocial Oncology Society.

26 Feb 2010

Helicos BioSciences to demonstrate single molecule sequencing using Helicos Genetic Analysis System

Helicos BioSciences and it’s collaborators will deliver presentations featured at the Advances in Genome Biology and Technology (AGBT) meeting in Marco Island, Florida, from February 24-27, 2010.

26 Feb 2010

EVA trial: MRI is more accurate for early diagnosis of breast cancer than digital mammography

Do we need a revision of current recommendations for breast cancer screening? According to a recent prospective multicenter cohort study published in the "Journal of Clinical Oncology", this appears advisable at least for young women carrying an increased risk of breast cancer. The results of the EVA trial confirm once more that magnetic resonance imaging (MRI) is substantially more accurate for early diagnosis of breast cancer than digital mammography or breast ultrasound: MRI is three times more sensitive for breast cancer than digital mammography.

26 Feb 2010

CPM procedure may only offer survival benefit to breast cancer patients age 50 and younger

Contralateral prophylactic mastectomy (CPM), a preventive procedure to remove the unaffected breast in patients with disease in one breast, may only offer a survival benefit to breast cancer patients age 50 and younger, who have early-stage disease and are estrogen receptor (ER) negative, according to researchers at The University of Texas M. D. Anderson Cancer Center.

26 Feb 2010

Alegent Health, TeleHealth Services partner in "Generation Patient" enhancement initiative

TeleHealth Services, the nation's leading provider of healthcare grade televisions and on-demand interactive patient education solutions, today announced an extended partnership with Alegent Health. Building upon an existing relationship, Alegent has chosen TeleHealth Services as its interactive patient education and entertainment partner in the health system's unprecedented "Generation Patient" enhancement initiative.

26 Feb 2010

Locally advanced sinonasal malignancies: Proton beam radiation therapy promising

Proton beam radiation therapy shows encouraging results for patients with locally advanced sinonasal malignancies, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

New dietary supplement blocks triggering mechanism causing breast cell mutations

Every 13 minutes a woman loses her battle with breast cancer and in 2009 alone more than 27,000 men died from prostate cancer. These powerful statistics continue to fuel research and new developments. With tens of millions of dollars in financial support from the National Cancer Institute and the U.S. Department of Defense, scientists have identified when estrogen metabolism is out of balance it can start the process leading to breast cell mutations.

26 Feb 2010

NCCN Guidelines: Chemosensitivity/resistance assays to be part of Principles of Chemotherapy section

Precision Therapeutics announced today that The National Comprehensive Cancer Network® recently updated the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer to include the use of chemosensitivity/resistance assays as part of the Principles of Chemotherapy section.

26 Feb 2010

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Using an accelerated, shorter course of radiation therapy for patients with advanced head and neck cancer allows doctors to reduce the amount of chemotherapy, thus reducing toxicity, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Genta initiates new dose-ranging study of tesetaxel drug

Genta Incorporated announced that the Company has initiated a new dose-ranging study of tesetaxel, the Company’s novel oral tubulin inhibitor, using a weekly dosing regimen. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

26 Feb 2010

Oncology News and Research

Further Reading

Acculis' new device for destroying unwanted tissues receives European CE Mark clearance

Cell Therapeutics files 2009 Annual Report on Form 10-K

Micrometastases in axillary lymph nodes associated with poorer overall survival in breast cancer patients

Vion Pharmaceuticals' Onrigin SPA: FDA responds

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

Magellan Health Services reports net revenue of $2.64 billion for year ended December 31, 2009

Larynx preservation using chemotherapy followed by radiation is effective treatment: Study

Integrative oncology program aims to address cancer patients' needs from every angle

Rapid, multiplexed genotyping method to identify SNPs that affect warfarin dose developed

imaGenes GmbH passes certification process to qualify as Roche NimbleGen CSP for DNA Methylation Analysis

Massaging advanced cancer patients for 14 minutes can reduce stress: Study

Helicos BioSciences to demonstrate single molecule sequencing using Helicos Genetic Analysis System

EVA trial: MRI is more accurate for early diagnosis of breast cancer than digital mammography

CPM procedure may only offer survival benefit to breast cancer patients age 50 and younger

Alegent Health, TeleHealth Services partner in "Generation Patient" enhancement initiative

Locally advanced sinonasal malignancies: Proton beam radiation therapy promising

New dietary supplement blocks triggering mechanism causing breast cell mutations

NCCN Guidelines: Chemosensitivity/resistance assays to be part of Principles of Chemotherapy section

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Genta initiates new dose-ranging study of tesetaxel drug

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News